Federal regulators have expanded US approval of a Vertex Pharmaceuticals Inc. cystic fibrosis drug, making it available to more than 900 new patients age 2 and over with specific genetic mutations. The Boston biotech said Wednesday that said the Food and Drug Administration OK’d the use of Kalydeco in patients who each have one of...